Acutus Medical, Inc. Provides Earnings Guidance for the Second Quarter Ending June 30, 2021
July 13, 2021 at 01:36 am IST
Share
Acutus Medical, Inc. provided earnings guidance for the second quarter ending June 30, 2021. For quarter, the company expected Preliminary net sales
to be in the range of $4.6 to $4.7 million. The Company estimates that its loss from operations on a GAAP basis for the quarter ended June 30, 2021 will be between $27.0 million and $29.0 million.
Acutus Medical, Inc. is focused on the production of left-heart access products under its distribution agreement with Medtronic, Inc. (Medtronic). The Company is solely focused on supporting the manufacturing and distribution of products to Medtronic. It manufactures transseptal crossing devices and associated accessories, such as integrated transseptal dilators and needles, fixed-curve or steerable introducers, and steerable sheaths (Products). These Products are used to access the left side, or left atrium, of the cardiac anatomy and are used in a range of medical applications, including in electrophysiology and structural heart procedures. The technology supports physicians during a critical component of an ablation or structural heart procedure. The transseptal crossing devices that it manufactures for Medtronic include versions that are length-, diameter- and tip-matched and designed to lock into the hub of sheaths used in many left-heart procedures.
ACUTUS MEDICAL, INC. 
